Inherited diseases of photoreceptors and prospects for gene therapy

Pharmacogenomics

Volumn 9, Issue 3, 2008, Pages 335-347

  Montana, Cynthia L ^a   Corbo, Joseph C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; cis regulation element; Gene therapy; Photoreceptors; Retina

Indexed keywords

ABC TRANSPORTER; ADENOVIRUS VECTOR; CILIARY NEUROTROPHIC FACTOR; GENE PRODUCT; PARVOVIRUS VECTOR; PROTEIN ABCA4; PRPH2 PROTEIN; RHODOPSIN; RPE65 PROTEIN; RPGRIP1 PROTEIN; RS1 PROTEIN; VISUAL PIGMENT;

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BYSTANDER EFFECT; CLINICAL TRIAL; COLOR BLINDNESS; DRUG EFFICACY; GENE ACTIVITY; GENE LOCUS; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; GENETIC HETEROGENEITY; HUMAN; NONHUMAN; PHOTORECEPTOR CELL; RETINA DEGENERATION; RETINA DISEASE; RETINITIS PIGMENTOSA; RETINOSCHISIS; REVIEW; RNA INTERFERENCE; TRANSGENE; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; GENETICS; HISTOLOGY; METHODOLOGY; PATHOLOGY; PHOTORECEPTOR; RETINA;

ADENO-ASSOCIATED VIRUS; ANIMALIA;

GENE THERAPY; HUMANS; PHOTORECEPTORS, VERTEBRATE; RETINA; RETINAL DISEASES;

EID: 42449147100     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.3.335     Document Type: Review

References (100)

1. Daiger SP: Identifying retinal disease genes: how far have we come, how far do we have to go? Novartis Found. Symp. 255, 17-27; discussion 27-36, 177-178 (2004).
2. Rattner A, Sun H, Nathans J: Molecular genetics of human retinal disease. Annu. Rev. Genet. 33, 89-131 (1999).
3. Blackshaw S, Fraioli RE, Furukawa T, Cepko CL: Comprehensive analysis of photoreceptor gene expression and the identification of candidate retinal disease genes. Cell 107, 579-589 (2001).
4. Hsiau TH, Diaconu C, Myers CA, Lee J, Cepko CL, Corbo JC: The cis-regulatory logic of the mammalian photoreceptor transcriptional network. PLoS ONE 2, E643 (2007).
5. Bainbridge JW, Tan MH, Ali RR: Gene therapy progress and prospects: the eye. Gene Ther. 13, 1191-1197 (2006).
6. Dinculescu A, Glushakova L, Min SH, Hauswith WW: Adeno-associated virus-vectored gene therapy for retinal disease. Hum. Gene Ther. 16, 649-663 (2005).
7. Allocca M, Tessitore A, Cotugno G, Auricchio A: AAV-mediated gene transfer for retinal diseases. Expert Opin. Biol. Ther. 6, 1279-1294 (2006).
8. Peeters L, Sanders NN, Demeester J, De Smedt SC: Challenges in non-viral ocular gene transfer. Biochem. Soc. Trans. 35, 47-49 (2007).
9. Andrieu-Soler C, Bejjani RA, de Bizemont T, Normand N, BenEzra D, Behar-Cohen F: Ocular gene therapy: a review of nonviral strategies. Mol. Vis. 12, 1334-1347 (2006).
10. Hartong DT, Berson EL, Dryja TP: Retinitis pigmentosa. Lancet 368, 1795-1809 (2006).
11. Rattner A, Nathans J: Macular degeneration: recent advances and therapeutic opportunities. Nat. Rev. Neurosci. 7, 860-872 (2006).
12. Campochiaro PA: Gene therapy for ocular neovascularization. Curr. Gene Ther. 7, 25-33 (2007).
13. Allikmets R: Leber congenital amaurosis: a genetic paradigm. Ophthalmic Genet. 25, 67-79, (2004).
14. Kremer H, van Wijk E, Marker T, Wolfrum U, Roepman R: Usher syndrome: molecular links of pathogenesis, proteins and pathways. Hum. Mol. Genet. 15(2), R262-R270 (2006).
15. Blacque OE, Leroux MR: Bardet-Biedl syndrome: an emerging pathomechanism of intracellular transport. Cell. Mol. Life & Sci. 63, 2145-2161 (2006).
16. Rodieck RW. The first steps in seeing. Sinauer, Sunderland, MA, USA (1998).
17. Cajal SRY: Histology of the nervous system of man and vertebrates. Oxford University Press, NY, USA (1995).
18. Curcio CA, Sloan KR, Kalina RE, Hendrickson AE: Human photoreceptor topography. J. Comp. Neurol. 292, 497-523 (1990).
19. Strauss O: The retinal pigment epithelium in visual function. Physiol. Rev. 85, 845-881 (2005).
20. Kajiwara K, Berson EL, Dryja TP: Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. Science 264, 1604-1608 (1994).
21. Katsanis N, Ansley SJ, Badano JL et al.: Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. Science 293, 2256-2259 (2001).
22. Bessant DA, Ali RR, Bhattacharya SS: Molecular genetics and prospects for therapy of the inherited retinal dystrophies. Curr. Opin. Genet. Dev. 11, 307-316 (2001).
23. Rozet JM, Gerber S, Souied E et al.: The ABCR gene: a major disease gene in macular and peripheral retinal degenerations with onset from early childhood to the elderly. Mol. Genet. Metab. 68, 310-315 (1999).
24. Stricker HM, Ding XQ, Quiambao A, Fliesler SJ, Naash MI: The Cys214->Ser mutation in peripherin/rds causes a loss-of-function phenotype in transgenic mice. Biochem. J. 388, 605-613 (2005).
25. Wilson JH, Wensel TC: The nature of dominant mutations of rhodopsin and implications for gene therapy. Mol. Neurobiol. 28, 149-158 (2003).
26. Mendes HF, van der Spuy J, Chapple JP, Cheetham ME: Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol. Med. 11, 177-185 (2005).
27. Illing ME, Rajan RS, Bence NF, Kopito RR: A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J. Biol. Chem. 277, 34150-34160 (2002).
28. Sung CH, Schneider BG, Agarwal N, Papermaster DS, Nathans J: Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proc. Natl Acad. Sci. USA 88, 8840-8844 (1991).
29. Milam AH, Li ZY, Fariss RN: Histopathology of the human retina in retinitis pigmentosa. Prog. Retin. Eye Res. 17, 175-205 (1998).
30. Lem J, Fain GL: Constitutive opsin signaling: night blindness or retinal degeneration? Trends Mol. Med. 10, 150-157 (2004).
31. Noell WK, Walker VS, Kang BS, Berman S: Retinal damage by light in rats. Invest. Ophthalmol. 5, 450-473 (1966).
32. Fain GL, Lisman JE: Photoreceptor degeneration in vitamin A deprivation and retinitis pigmentosa: the equivalent light hypothesis. Exp. Eye Res. 57. 335-340 (1993).
33. Fain GL: Why photoreceptors die (and why they don't). Bioessays 28, 344-354 (2006).
34. Hao W, Wenzel A, Obin MS et al.: Evidence for two apoptotic pathways in light-induced retinal degeneration. Nat. Genet. 32, 254-260 (2002).
35. Woodruff ML, Wang Z, Chung HY, Redmond TM, Fain GL, Lem J: Spontaneous activity of opsin apoprotein is a cause of Leber congenital amaurosis. Nat. Genet. 35, 158-164 (2003).
36. Herskowitz I: Functional inactivation of genes by dominant negative mutations. Nature 329, 219-222 (1987).
37. Coppieters F, Leroy BP, Beysen D et al.: Recurrent mutation in the first zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosa. Am. J. Hum. Genet. 81, 147-157 (2007).
38. Bessant DA, Payne AM, Mitton KP et al.: A mutation in NRL is associated with autosomal dominant retinitis pigmentosa. Nat. Genet. 21, 355-356 (1999).
39. Reiners J, Nagel-Wolfrum K, Jurgens K, Marker T, Wolfrum U: Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease. Exp. Eye Res. 83, 97-119 (2006).
40. Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA: New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J. Med. Genet. 36, 437-446 (1999).
41. Corbo JC, Myers CA, Lawrence KA, Jadhav AP, Cepko CL: A typology of photoreceptor gene expression patterns in the mouse. Proc. Natl Acad. Sci. USA 104, 12069-12074 (2007).
42. Sisodiya SM, Thompson PJ, Need A et al.: Genetic enhancement of cognition in a kindred with cone-rod dystrophy due to RIMS1 mutation. J. Med. Genet. 44, 373-380 (2007).
43. Powell CM, Schoch S, Monteggia L et al.: The presynaptic active zone protein RIM1α is critical for normal learning and memory. Neuron 42, 143-153 (2004).
44. Kaeser PS, Sudhof TC: RIM function in short- and long-term synaptic plasticity. Biochem. Soc. Trans. 33, 1345-1349 (2005).
45. Applebury ML, Antoch MP, Baxter LC et al.: The murine cone photoreceptor: a single cone type expresses both S and M opsins with retinal spatial patterning. Neuron 27, 513-523 (2000).
46. Kohl S, Varsanyi B, Antunes CA et al.: CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. Eur. J. Hum. Genet. 13, 302-308 (2005).
47. Hicks D, Sahel J: The implications of rod-dependent cone survival for basic and clinical research. Invest. Ophthalmol. Vis. Sci. 40, 3071-3074 (1999).
48. Leveillard T, Mohand-Said S, Lorentz O et al.: Identification and characterization of rod-derived cone viability factor. Nat. Genet. 36, 755-759 (2004).
49. Ripps H: Cell death in retinitis pigmentosa: gap junctions and the 'bystander' effect. Exp. Eye Res. 74, 327-336 (2002).
50. Mears AJ, Kondo M, Swain PK et al.: Nr1 is required for rod photoreceptor development. Nat. Genet. 29, 447-452 (2001).
51. Daniele, LL, Lillo C, Lyubarsky AL et al.: Cone-like morphological, molecular, and electrophysiological features of the photoreceptors of the Nr1 knockout mouse. Invest. Ophthalmol. Vis. Sci. 46, 2156-2167 (2005).
52. Khan NW, Wissinger B, Kohl S, Sieving PA: CNGB3 achromatopsia with progressive loss of residual cone function and impaired rod-mediated function. Invest. Ophthalmol. Vis. Sci. 48, 3864-3871 (2007).
53. Hisatomi T, Sakamoto T, Sonoda KH et al.: Clearance of apoptotic photoreceptors: elimination of apoptotic debris into the subretinal space and macrophage-mediated phagocytosis via phosphatidylserine receptor and integrin alphavbeta3. Am. J. Pathol. 162, 1869-1879 (2003).
54. Lobsiger CS, Cleveland DW: Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat. Neurosci. 10, 1355-1360 (2007).
55. Pawlyk BS, Smith AJ, Buch PK et al.: Gene replacement therapy rescues photoreceptor degeneration in a murine model of Leber congenital amaurosis lacking RPGRIP. Invest. Ophthalmol. Vis. Sci. 46, 3039-3045 (2005).
56. Zeng Y, Takada Y, Kjellstrom S et al.: RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis. Invest. Ophthalmol. Vis. Sci. 45, 3279-3285 (2004).
57. Smith AJ, Schlichtenbrede FC, Tschemutter M, Bainbridge JW, Thrasher AJ, Ali RR: AAV-mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol. Ther. 8, 188-195 (2003).
58. Narfstrom K, Katz ML, Ford M, Redmond TM, Rakoczy E, Bragadottir R: In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement. J. Hered. 94, 31-37 (2003).
59. Goverdhana S, Puntel M, Xiong W et al.: Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol. Ther. 12, 189-211 (2005).
60. Takahashi M, Miyoshi H, Verma IM, Gage FH: Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J. Virol. 73, 7812-7816 (1999).
61. Bennett J, Tanabe T, Sun D et al.: Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat. Med. 2, 649-654 (1996).
62. Kumar-Singh R, Farber DB: Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration. Hum. Mol. Genet. 7, 1893-1900 (1998).
63. Alexander JJ, Umino Y, Everhart D et al.: Restoration of cone vision in a mouse model of achromatopsia. Nat. Med. 13, 685-687 (2007).
64. Bemelmans AP, Kostic C, Crippa SV et al.: Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis. PLoS Med. 3, E347 (2006).
65. Bainbridge JW, Stephens C, Parsley K et al.: In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther. 8, 1665-1668 (2001).
66. Gruter O, Kostic C, Crippa SV et al.: Lentiviral vector-mediated gene transfer in adult mouse photoreceptors is impaired by the presence of a physical barrier. Gene Ther: 12, 942-947 (2005).
67. Pang J, Cheng M, Haire SE, Barker E, Planelles V, Blanks JC: Efficiency of lentiviral transduction during development in normal and rd mice. Mol. Vis. 12, 756-767 (2006).
68. Pang J, Cheng M, Stevenson D, Trousdale MD, Dorey CK, Blanks JC: Adenoviral-mediated gene transfer to retinal explants during development and degeneration. Exp. Eye Res. 79, 189-201. (2004).
69. Cashman SM, McCullough L, Kumar-Singh R: Improved retinal transduction in vivo and photoreceptor-specific transgene expression using adenovirus vectors with modified penton base. Mol. Ther. 15, 1640-1646 (2007).
70. Hong DH, Pawlyk BS, Adamian M, Sandberg MA, Li T: A single, abbreviated RPCR-ORF15 variant reconstitutes RPGR function in vivo, Invest. Ophthalmol. Vis. Sci. 46, 435-441 (2005).
71. Ali RR, Sarra GM, Stephens C et al.: Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat. Genet. 25, 306-310 (2000).
72. Schlichtenbrede FC, Smith AJ, Bainbridge JW, Thrasher AJ, Salt TE, Ali RR: Improvement of neuronal visual responses in the superior colliculus in Prph2(Rd21 Rd2) mice following gene therapy. Mol. Cell. Neurosci. 25, 103-110 (2004).
73. Min SH, Molday LL, Seeliger MW et al.: Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. Mol. Ther. 12, 644-651 (2005).
74. Khani SC, Pawlyk BS, Bulgakov OV et al.: AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter. Invest. Ophthalmol. Vis. Sci. 48, 3954-3961 (2007).
75. Farrar GJ, Kenna PF, Humphries P: On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J. 21, 857-864 (2002).
76. O'Reilly M, Palfi A, Chadderton N et al.: RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am. J. Hum. Genet. 81, 127-135 (2007).
77. Sarra GM, Stephens C, Schlichtenbrede FC et al.: Kinetics of transgene expression in mouse retina following sub-retinal injection of recombinant adeno-associated virus. Vision Res. 42, 541-549 (2002).
78. Woodruff ML, Olshevskaya EV, Savchenko AB et al.: Constitutive excitation by Gly90Asp rhodopsin rescues rods from degeneration caused by elevated production of cGMP in the dark. J. Neurosci. 27, 8805-8815 (2007).
79. Payne AM, Downes SM, Bessant DA et al.: A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1. Hum. Mol. Genet. 7, 273-277 (1998).
80. + and causes photoreceptor degeneration in transgenic mice. J. Neurosci. 24, 6078-6085 (2004).
81. Sieving PA, Fowler ML, Bush RA et al.: Constitutive "light" adaptation in rods from G90D rhodopsin: a mechanism for human congenital nightblindness without rod cell loss. J Neurosci. 21, 5449-5460 (2001).
82. Portera-Cailliau C, Sung CH, Nathans J, Adler R: Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa. Proc. Natl Acad. Sci. USA 91, 974-978 (1994).
83. Reme CE, Grimm C, Hafezi F, Marti A, Wenzel A: Apoptotic cell death in retinal degenerations. Prog. Retin. Eye Res. 17, 443-464 (1998).
84. LaVail MM, Yasumura D, Matthes MT et al.: Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest. Ophthalmol. Vis. Sci. 39, 592-602 (1998).
85. Tao W, Wen R, Goddard MB et al.: Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in aninial models of retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 43, 3292-3298 (2002).
86. Liang FQ, Dejneka NS, Cohen DR et al.: AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. Mol. Ther. 3, 241-248 (2001).
87. Bok D: Ciliary neurotrophic factor therapy for inherited retinal diseases: pros and cons. Retina 25, S27-S28 (2005).
88. McGill TJ, Prusky GT, Douglas RM et al.: Intraocular CNTF reduces vision in normal rats in a dose-dependent manner. Invest. Ophthalmol. Vis. Sci. 48, 5756-5766 (2007).
89. Sieving PA, Caruso RC, Tao W et al.: Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc. Natl Acad. Sci. USA 103, 3896-3901 (2006).
90. Bainbridge JW: Gene therapy clinical trials for inherited eye disease. Expert Rev. Ophthalmol. 2, 517-519 (2007).
91. Acland GM, Aguirre GD, Ray J et al.: Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28, 92-95 (2001).
92. Le Meur G, Stieger K, Smith AJ et al.: Restoration of vision in RPE65 deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther. 14, 292-303 (2007).
93. Retracing events. Nat. Biotechnol. 25, 949 (2007).
94. Donsante A, Vogler C, Muzyczka N et al.: Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 8, 1343-1346 (2001).
95. Donsante A, Miller DG, Li Y et al.: AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477 (2007).
96. Waehler R, Russell SJ, Curiel DT: Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 8, 573-587 (2007).
97. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV: Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198-204 (2006).
98. Glushakova LG, Timmers AM, Pang J, Teusner JT, Hauswirth WW: Human blue-opsin promoter preferentially targets reporter gene expression to rat S-cone photoreceptors. Invest. Ophthalmol. Vis. Sci. 47, 3505-3513 (2006).
99. Li Q. Timmers AM, Guy J, Pang J, Hauswirth WW: Cone-specific expression using a human red opsin promoter in recombinant AAV. Vision Res. (2007 (Epub ahead of print).
100. Mancuso K, Hendrickson AE, Connor TB Jr et al.: Recombinant adeno-associated virus targets passenger gene expression to cones in primate retina. J. Opt. Soc Am. A Opt. Image Sci. Vis. 24, 1411-1416 (2007).